Fungal protein reagent kit for allergic airway drug screening
This patent covers isolated proteins and genetic sequences from fungi that trigger specific immune responses in humans, particularly the activation and degranulation of eosinophils — a type of white blood cell heavily involved in allergic and inflammatory reactions. The technology provides tools to study how certain fungal proteins cause inflammation and to screen candidate drugs that might block that process. Essentially, it gives researchers defined molecular targets and assay methods to understand and potentially interrupt fungus-driven allergic disease.
What you could build
A drug-screening platform or research reagent kit for pharmaceutical and biotech companies developing therapies for fungal-induced asthma, allergic bronchopulmonary aspergillosis, or eosinophilic sinusitis; buyers would be allergy/immunology-focused biotech and pharma R&D groups.
Who in Virginia should care
Biotech and pharmaceutical companies in the Northern Virginia/DC corridor or near Virginia research universities with allergy and immunology programs would be the most plausible contacts.
Readiness: Concept
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- HIROHITO KITA, JENS PONIKAU, CHRISTOPHER LAWRENCE
- Granted
- February 15, 2011
- Status
- Granted patent
- Patent number
- 7887820
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.